Chemed Corporation reported a 6.0% increase in revenue to $532 million for Q2 2021. GAAP EPS decreased by 29.9% to $3.51, while adjusted EPS increased by 4.3% to $4.60. The VITAS segment experienced declines in net patient revenue and ADC, while the Roto-Rooter segment saw significant revenue growth.
Consolidated revenue increased by 6.0% to $532 million.
GAAP diluted EPS decreased by 29.9% to $3.51.
Adjusted diluted EPS increased by 4.3% to $4.60.
Roto-Rooter revenue increased by 26.1% to $220 million.
Chemed increased its full-year 2021 adjusted earnings per diluted share guidance to a range of $18.20 to $18.50, compared to the initial guidance of $17.00 to $17.50.
Visualization of income flow from segment revenue to net income